ADC Therapeutics SA Comprehensive Income Attributable To Owners Of Parent
ADC Therapeutics SA (ADCT) reported Comprehensive Income Attributable To Owners Of Parent of -$48.02 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent · last filed 2023-11-07
- ADC Therapeutics SA comprehensive income attributable to owners of parent for the quarter ending 2023-09-30 was -$48.02M.
- ADC Therapeutics SA comprehensive income attributable to owners of parent for the quarter ending 2023-06-30 was -$47.39M.
- ADC Therapeutics SA comprehensive income attributable to owners of parent for the quarter ending 2023-03-31 was -$59.54M.
- ADC Therapeutics SA comprehensive income attributable to owners of parent for the quarter ending 2022-12-31 was -$23.57M.
| Period end | Comprehensive Income Attributable To Owners Of Parent 3 month | Comprehensive Income Attributable To Owners Of Parent 6 month | Comprehensive Income Attributable To Owners Of Parent 9 month | Comprehensive Income Attributable To Owners Of Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$48.02M 6-K · filed 2023-11-07 | -$95.42M derived: sum of 2 quarters · filed 2023-11-07 | -$154.96M 6-K · filed 2023-11-07 | -$178.53M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$47.39M 6-K · filed 2023-08-08 | -$106.93M 6-K · filed 2023-08-08 | -$130.51M derived: sum of 3 quarters · filed 2023-08-08 | -$181.60M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$59.54M 6-K · filed 2023-05-09 | -$83.11M derived: sum of 2 quarters · filed 2023-05-09 | -$134.21M derived: sum of 3 quarters · filed 2023-11-07 | -$195.35M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$23.57M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$74.67M derived: sum of 2 quarters · filed 2023-11-07 | -$135.81M derived: sum of 3 quarters · filed 2023-11-07 | -$152.62M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$51.09M 6-K · filed 2023-11-07 | -$112.23M derived: sum of 2 quarters · filed 2023-11-07 | -$129.05M 6-K · filed 2023-11-07 | -$164.00M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$61.14M 6-K · filed 2023-08-08 | -$77.96M 6-K · filed 2023-08-08 | -$112.90M derived: sum of 3 quarters · filed 2023-08-08 | -$184.59M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$16.82M 6-K · filed 2023-05-09 | -$51.77M derived: sum of 2 quarters · filed 2023-05-09 | -$123.45M derived: sum of 3 quarters · filed 2023-05-09 | -$196.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$34.95M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$106.64M derived: sum of 2 quarters · filed 2023-03-15 | -$179.18M derived: sum of 3 quarters · filed 2023-03-15 | -$230.68M 20-F · filed 2023-03-15 |
| 2021-09-30 | -$71.69M 6-K · filed 2022-11-08 | -$144.24M derived: sum of 2 quarters · filed 2022-11-08 | -$195.73M 6-K · filed 2022-11-08 | -$251.72M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$72.55M 6-K · filed 2022-08-09 | -$124.04M 6-K · filed 2022-08-09 | -$180.03M derived: sum of 3 quarters · filed 2023-03-15 | -$200.21M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$51.49M 6-K · filed 2022-05-09 | -$107.48M derived: sum of 2 quarters · filed 2023-03-15 | -$127.66M derived: sum of 3 quarters · filed 2023-03-15 | -$254.23M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$55.99M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$76.17M derived: sum of 2 quarters · filed 2023-03-15 | -$202.74M derived: sum of 3 quarters · filed 2023-03-15 | -$246.42M 20-F · filed 2023-03-15 |
| 2020-09-30 | -$20.18M 6-K · filed 2021-11-02 | -$146.75M derived: sum of 2 quarters · filed 2021-11-02 | -$190.43M 6-K · filed 2021-11-02 | |
| 2020-06-30 | -$126.57M 6-K · filed 2021-08-03 | -$170.25M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$43.68M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$117.72M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$123.37M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |